Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Chronic Lymphocytic Leukemia (CLL) Market Report Overview
The Chronic Lymphocytic Leukemia (CLL) market value for the 15 markets (15M) was $13.2 billion in 2021. This included both cell therapies and established/traditional CLL therapies. The 15 markets comprise the 8 major markets and seven countries known to have increased potential for cell therapies given the current drug development landscape, namely Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada.
The CLL market research report includes an assessment of the disease epidemiology and a 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for chronic lymphocytic leukemia (CLL).
CLL Market Drivers and Unmet Needs
CAR-T usage in patients with del17p/TP53 mutations will be driven by the unmet need for more treatments that can induce long-term disease control. Also, CAR-T is an attractive option for R/R patients who have progressed on targeted therapy.
Long-term disease control in patients with del17p/Tp53 mutations is one of the unmet needs of the CLL market. Specifically, high-risk CLL patients with del17p/TP53 typically respond well initially to targeted therapy but often relapse or progress far more quickly than non-mutated patients, therefore quickly exhausting the available treatment options.
To know more about the Chronic Lymphocytic Leukemia drivers in the CLL Market, download a free report sample
CLL Market Segmentation by Regions
The key regions in the CLL market are North America, APAC, Europe, and the Middle East. North America had the highest share in 2021.
Chronic Lymphocytic Leukemia Market Analysis by Regions, 2021 (%)
For more regional insights on the Chronic Lymphocytic Leukemia market, download a free report sample
CLL Market - Competitive Landscape
Some of the future players in the CLL market are Juno Therapeutics, Shanghai Simnova Biotechnology Co Ltd, Shanghai YaKe Biotechnology Co Ltd, Beijing GoBroad Hospital management Co. Ltd, and Wuhan Bio-Raid Biotechnology Co Ltd. Chinese biotech company Sian Wuhan Medical Technology Co Ltd leads with the highest number of ongoing clinical trials for its autologous CAR-T agent SACD19-101, which is currently in four different ongoing clinical trials in China, including Phase III.
For more insights on companies in the CLL market, download a free report sample
CLL Market Report Overview
Market Size (2021 in 15M) | $13.2 billion |
Key Regions | North America, APAC, Europe, and The Middle East |
Future Players | Juno Therapeutics, Shanghai Simnova Biotechnology Co Ltd, Shanghai YaKe Biotechnology Co Ltd, Beijing GoBroad Hospital management Co. Ltd, and Wuhan Bio-Raid Biotechnology Co Ltd |
Scope
- This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action, and cell & gene therapies by class, including early- to late clinical-stage pipeline products with launch date assessment by the 8 major markets.
- The forecast includes 8 countries for the period of 2021-2031.
- Seven markets are extrapolated, obtaining a 15-market value for all CLL therapeutics
Reasons to Buy
- Obtain cell therapy sales forecasts across multiple regions
- Gain insight into promising early stage approaches
- Our indication specific forecast models answer questions such as:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Autolus Therapeutics
Sian Wuhan Medical Technology
Table of Contents
Frequently asked questions
-
What was the CLL market size in the 15M in 2021?
The CLL market value for the 15 markets (15M) was $13.2 billion in 2021.
-
Which are the key regions in the CLL market?
The key regions in the CLL market are North America, APAC, Europe, and the Middle East.
-
Which region had the highest share in the CLL market?
North America had the highest share of the CLL market.
-
Who are the future players in the CLL market?
Some of the future players in the CLL market are Juno Therapeutics, Shanghai Simnova Biotechnology Co Ltd, Shanghai YaKe Biotechnology Co Ltd, Beijing GoBroad Hospital Management Co. Ltd, and Wuhan Bio-Raid Biotechnology Co Ltd.
-
Which player has the highest number of products in the CLL market?
Chinese biotech company Sian Wuhan Medical Technology Co Ltd leads with the highest number of ongoing clinical trials for its autologous CAR-T agent SACD19-101, which is currently in four different ongoing clinical trials in China, including Phase III.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Chronic Lymphocytic Leukemia (CLL) reports

